Astellas Pharma Future Growth
Future criteria checks 3/6
Astellas Pharma is forecast to grow earnings and revenue by 30% and 3.4% per annum respectively. EPS is expected to grow by 32.5% per annum. Return on equity is forecast to be 15.6% in 3 years.
Key information
30.0%
Earnings growth rate
32.5%
EPS growth rate
Pharmaceuticals earnings growth | 19.6% |
Revenue growth rate | 3.4% |
Future return on equity | 15.6% |
Analyst coverage | Good |
Last updated | 10 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
3/31/2027 | 1,940,289 | 271,884 | 352,249 | 401,028 | 8 |
3/31/2026 | 1,774,821 | 200,361 | 296,539 | 360,344 | 14 |
3/31/2025 | 1,669,742 | 140,278 | 243,623 | 292,761 | 15 |
3/31/2024 | 1,571,512 | 74,373 | -582,565 | 249,416 | 15 |
12/31/2023 | 1,543,324 | 4,198 | 136,404 | 216,089 | N/A |
9/30/2023 | 1,523,572 | 38,090 | 151,562 | 236,992 | N/A |
6/30/2023 | 1,511,818 | 107,031 | 205,852 | 291,133 | N/A |
3/31/2023 | 1,518,619 | 98,714 | 239,438 | 327,767 | N/A |
12/31/2022 | 1,468,235 | 136,430 | 183,399 | 260,759 | N/A |
9/30/2022 | 1,406,682 | 148,911 | 214,107 | 257,916 | N/A |
6/30/2022 | 1,351,811 | 118,211 | 215,849 | 266,193 | N/A |
3/31/2022 | 1,296,163 | 124,086 | 205,277 | 257,444 | N/A |
12/31/2021 | 1,300,914 | 120,167 | 236,959 | 290,559 | N/A |
9/30/2021 | 1,285,714 | 119,360 | 248,993 | 331,268 | N/A |
6/30/2021 | 1,268,702 | 100,863 | 261,235 | 325,326 | N/A |
3/31/2021 | 1,249,528 | 120,589 | 229,402 | 306,843 | N/A |
12/31/2020 | 1,253,215 | 138,307 | 196,679 | 276,851 | N/A |
9/30/2020 | 1,265,853 | 139,722 | 146,751 | 235,299 | N/A |
6/30/2020 | 1,273,678 | 187,306 | 135,534 | 236,186 | N/A |
3/31/2020 | 1,300,843 | 195,411 | 144,110 | 221,998 | N/A |
12/31/2019 | 1,289,855 | 220,751 | 151,021 | 225,239 | N/A |
9/30/2019 | 1,309,722 | 246,925 | 182,693 | 248,203 | N/A |
6/30/2019 | 1,311,397 | 226,224 | 176,251 | 228,863 | N/A |
3/31/2019 | 1,306,348 | 222,265 | 206,502 | 258,630 | N/A |
12/31/2018 | 1,305,901 | 213,600 | 254,876 | 300,955 | N/A |
9/30/2018 | 1,307,658 | 186,429 | 265,976 | 309,442 | N/A |
6/30/2018 | 1,306,830 | 176,770 | 246,040 | 290,301 | N/A |
3/31/2018 | 1,300,316 | 164,679 | 272,329 | 312,614 | N/A |
12/31/2017 | 1,305,521 | 182,515 | 223,584 | 264,549 | N/A |
9/30/2017 | 1,299,746 | 185,754 | N/A | 260,795 | N/A |
6/30/2017 | 1,296,484 | 194,556 | N/A | 276,954 | N/A |
3/31/2017 | 1,311,665 | 218,701 | N/A | 235,612 | N/A |
12/31/2016 | 1,312,627 | 207,940 | N/A | 325,459 | N/A |
9/30/2016 | 1,336,878 | 205,818 | N/A | 308,800 | N/A |
6/30/2016 | 1,366,799 | 215,678 | N/A | 302,245 | N/A |
3/31/2016 | 1,372,706 | 193,687 | N/A | 313,737 | N/A |
12/31/2015 | 1,360,153 | 185,659 | N/A | 207,806 | N/A |
9/30/2015 | 1,340,307 | 168,805 | N/A | 182,815 | N/A |
6/30/2015 | 1,295,761 | 144,617 | N/A | 156,675 | N/A |
3/31/2015 | 1,247,259 | 135,856 | N/A | 187,686 | N/A |
12/31/2014 | 1,205,276 | 124,154 | N/A | N/A | N/A |
9/30/2014 | 1,177,660 | 112,663 | N/A | 224,809 | N/A |
6/30/2014 | 1,159,218 | 104,614 | N/A | N/A | N/A |
3/31/2014 | 1,139,909 | 90,874 | N/A | 214,257 | N/A |
12/31/2013 | 1,137,824 | 79,679 | N/A | N/A | N/A |
9/30/2013 | 1,085,481 | 73,641 | N/A | 183,507 | N/A |
6/30/2013 | 1,038,227 | 69,483 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 4503 N's forecast earnings growth (30% per year) is above the savings rate (7.7%).
Earnings vs Market: 4503 N's earnings (30% per year) are forecast to grow faster than the MX market (9.7% per year).
High Growth Earnings: 4503 N's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 4503 N's revenue (3.4% per year) is forecast to grow slower than the MX market (6.9% per year).
High Growth Revenue: 4503 N's revenue (3.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 4503 N's Return on Equity is forecast to be low in 3 years time (15.6%).